posted on 2017-11-18, 00:00authored byNatania A Crane, Lisanne M. Jenkins, Catherine Dion, Kortni K. Meyers, Anne L. Weldon, Laura B. Gabriel, Sara J. Walker, David T. Hsu, Douglas C. Noll, Heide Klumpp, K. Luan Phan, Jon-Kar Zubieta, Scott A. Langenecker
Background: Major Depressive Disorder (MDD) and anxiety disorders often co-occur, with
poorer treatment response and long-term outcomes. However, little is known about the shared
and distinct neural mechanisms of comorbid MDD and anxiety (MDD+Anx). This study
examined how MDD and MDD+Anx differentially impact cognitive control.
Methods: Eighteen MDD, 29 MDD+Anx, and 54 healthy controls (HC) completed the
Parametric Go/No-go (PGNG) during fMRI, including Target, Commission and Rejection trials.
Results: MDD+Anx had more activation in the anterior dorsolateral prefrontal cortex,
hippocampus, and caudate during Rejections, and inferior parietal lobule during correct Targets
than MDD and HC. During Rejections HC had greater activation in a number of cognitive
control regions compared to MDD; in the posterior cingulate compared to MDD+Anx; and in the
fusiform gyrus compared to all MDD. During Commissions HC had greater activation in the
right inferior frontal gyrus than all MDD. MDD had more activation in the mid-cingulate,
inferior parietal lobule, and superior temporal gyrus than MDD+Anx during Commissions.
Conclusions: Despite similar performance, MDD and MDD+Anx showed distinct differences in
neural mechanisms of cognitive control in relation to each other, as well as some shared
differences in relation to HC. The results were consistent with our hypothesis of hypervigilance
in MDD+Anx within the cognitive control network, but inconsistent with our hypothesis that
there would be greater engagement of salience and emotion network regions. Comorbidity of
depression and anxiety may cause increased heterogeneity in study samples, requiring further
specificity in detection and measurement of intermediate phenotypes and treatment targets.